Labcorp to buy select assets from Opko Health unit for up to $872 million

By Reuters News

Oct 15 (Reuters) - Laboratory operator Labcorp LH.N said on Thursday it will buy some assets from Opko Health's OPK.O subsidiary in a $722 million cash deal, with a potential additional payment of up to $150 million tied to revenue from a prostate cancer test.

Shares of Opko Health were up 20% in premarket trading.


Here are some details:

  • Under the agreement, Labcorp will acquire Opko's BioReference Health laboratory testing operations, including its clinical diagnostics, women's health, urology and corrections testing businesses

  • Labcorp will gain more than 80 patient service centers and certain operating assets from the deal

  • It will also get ownership of BioReference's 4Kscore test, which is used to help assess the likelihood of aggressive prostate cancer before a patient undergoes a biopsy. The test brought in revenue of $27.1 million in 2025

  • The Burlington, North Carolina-based company expects the acquired businesses to generate about $250 million in revenue in the first year after the transaction closes

  • The deal requires regulatory clearance and other closing conditions. The companies did not provide an expected closing date

  • Miami-based Opko said the sale will streamline its operations and sharpen its focus on its biopharmaceutical business, which includes its FDA-approved kidney disease therapy Rayaldee

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.